2025-09-15 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co (LLY), combining the provided data points into a structured report.

## Eli Lilly and Co (LLY) Stock Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** LLY
*   **Company Description:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**Key Performance Numbers:**

*   **LLY Cumulative Return:** 229.92%
*   **VOO (S&P 500) Cumulative Return:** 104.48%
*   **Absolute Divergence (LLY - VOO):** 125.44%
*   **Divergence Range:**
    *   Max: 307.4
    *   Min: -12.8
    *   Current: 128.7
*   **Relative Divergence:** 44.2 (This indicates LLY's outperformance is in the 44.2 percentile of its historical divergence range from VOO.)

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period examined. The relative divergence suggests that while the outperformance is substantial, there's potential for further gains relative to its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
|------------|--------|--------|--------|-------|--------|
| 2015-2017  | 10.0%  | 56.3%  | -19.0% | 0.0   | 75.7   |
| 2016-2018  | 39.0%  | 58.6%  | 21.0%  | -0.1  | 103.7  |
| 2017-2019  | 50.0%  | 58.6%  | 20.0%  | 0.3   | 117.8  |
| 2018-2020  | 52.0%  | 58.6%  | 33.0%  | 0.1   | 151.4  |
| 2019-2021  | 106.0% | 60.6%  | 57.0%  | 0.2   | 247.6  |
| 2020-2022  | 98.0%  | 64.8%  | 96.0%  | 0.2   | 328.0  |
| 2021-2023  | 133.0% | 64.8%  | 115.0% | 0.3   | 522.6  |
| 2022-2024  | 150.0% | 72.2%  | 124.0% | 0.2   | 692.1  |
| 2023-2025  | 83.0%  | 76.8%  | 26.0%  | 0.2   | 677.2  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR demonstrates strong growth, particularly in recent years.
*   **MDD (Maximum Drawdown):** The MDD figures indicate significant volatility and potential risk in downturns.
*   **Alpha:** Consistently positive and high Alpha values suggest LLY is generating returns above what would be expected based on its market exposure (S&P 500). Recent alpha values have been exceptionally high.
*   **Beta:** Beta values are relatively low, indicating that LLY's price is less sensitive to overall market movements than the S&P 500.
*   **Cap (B):**  The market capitalization has grown substantially over the years, showing strong investor confidence and growth in the company's value.

### 2. Recent Stock Price Movement

*   **Current Price:** $755.39
*   **Previous Close:** $756.28
*   **Change:** -$0.12 (-0.01%)
*   **5-day Moving Average:** 751.108
*   **20-day Moving Average:** 727.9
*   **60-day Moving Average:** 748.4085

**Analysis:** The current price is slightly down from the previous close. The 5-day moving average is above the 20-day moving average, which is above the 60-day moving average, suggesting an upward trend in the short to medium term.

### 3. Technical Indicators & Return Expectation

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI (Relative Strength Index):** 68.56 (Approaching overbought territory)
*   **PPO (Percentage Price Oscillator):** 0.7604
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **20-day Relative Divergence Change:** +2.8 (Short-term increase)
*   **Expected Return:** 207.2% (Long-term, relative to S&P 500)

**Analysis:**

*   The MRI suggests a low level of market risk.
*   The RSI nearing 70 suggests the stock may be approaching overbought conditions, indicating a potential pullback in the short term.
*   The PPO indicates the short-term moving average is above the long-term moving average, confirming the upward trend.
*   The Hybrid Signal recommends a partial buy, but with caution.
*   The positive change in relative divergence further supports the recent upward momentum.
*   The expected return of 207.2% is very optimistic, suggesting significant outperformance versus the S&P 500 over the long term with dollar cost averaging.
*   The slight decrease in price from the previous close indicates a minor pullback, but it's not significant enough to indicate a major trend reversal.

### 4. Recent News & Analyst Opinions

**Recent News (Yahoo Finance):**

*   Several articles highlight LLY as a strong stock for long-term holding, focusing on its growth potential.
*   Eli Lilly launched a "Brain Health Matters" campaign with Julianne Moore to promote Alzheimer’s Disease Awareness.
*   Discussion about how investors may respond to Eli Lilly's AI drug platform launch and oncology breakthroughs.

**Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.68 (~Buy)
*   **Number of Opinions:** 26
*   **Target Price (avg/high/low):** $891.62 / $1190.00 / $650.00

**Analysis:** Recent news is positive, with multiple articles suggesting LLY is a strong long-term investment. Analyst consensus is also bullish, with a "Buy" rating and an average target price significantly above the current price.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2025-08-07 | 3.29 | 11.30 B$   |

**Analysis:** The most recent quarter (2025-08-07) shows a very high EPS and strong revenue.  Revenue and EPS have generally been increasing, indicating positive growth momentum.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%       |
| 2025-03-31 | $12.73B   | 82.53%       |
| 2024-12-31 | $13.53B   | 82.24%       |
| 2024-09-30 | $11.44B   | 81.02%       |
| 2024-06-30 | $11.30B   | 80.80%       |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $18.27B   | 30.98%    |
| 2025-03-31 | $15.76B   | 17.50%    |
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |

**Analysis:**

*   **Revenue:** Increasing revenue over the quarters indicates strong sales and market demand for LLY's products.
*   **Profit Margin:**  Exceptionally high and increasing profit margins suggest strong pricing power and efficient cost management.
*   **Equity:** Increasing equity indicates the company is building its net worth.
*   **ROE (Return on Equity):** ROE is strong, indicating efficient use of shareholder equity to generate profits.

### 7. Overall Summary

Eli Lilly and Co. (LLY) appears to be a strong investment based on the provided data.

*   **Performance:**  Significantly outperforming the S&P 500.
*   **Technicals:** Upward trend, but RSI approaching overbought.
*   **News & Sentiment:** Positive news coverage and strong analyst ratings.
*   **Financials:** Strong revenue growth, high profit margins, and efficient use of equity.
*   **Risks:** High MDD indicating significant volatility, potential short-term pullback due to overbought RSI.
*   **Hybrid Signal:** Take partial buy position.
*   **Long-term Expected Return:** The expected return of 207.2% suggests considerable long-term outperformance.
